Slide 1: Unleashing tools to accelerate breakthroughs in human health
Unleashing tools to accelerate breakthroughs in human health™
Slide 2: Third Quarter 2022 Financial Results
THIRD QUARTER 2022 FINANCIAL RESULTS NOVEMBER 8, 2022 Standard BioTools
Slide 3: Legal Information
Legal Information Use of Forward-Looking Statements 10-K for the year ended December 31, 2021, and in its other filings with the Securities and This presentation and the accompanying oral presentation contain forward-looking statements Exchange Commission. These forward-looking statements speak only
Slide 4: CEO Commentary
CEO Commentary Michael Egholm, PhD Standard BioTools
Slide 5: Core Revenue Growth
C o re Re ve nu e G row t h + 30 % S e q ue nti a l l y LEVERAGE IMPROVE ACQUIRE Existing brand and product Standard BioTools™ Complementary and lines Business Systems (SBS) de-risked technology Seasoned management acquisitions Established global team to drive strategy and infrastructure e
Slide 6: Elements Required to Execute
E l e m e nt s Re qu ire d to E xe c ute LAB Platform Strategic M&A Create a diversified, innovation- Execute on highly strategic M&A focused life science tools company across a broad target universe serving the pharma research markets leveraging existing infrastructure Top-Grade Team Access to Capi
Slide 7: Strategic Priorities
S t rate g i c P r i o r i ti e s 1. Revenue Growth Third quarter core product and services revenue increase of 30% sequentially to $24.8 million Sequential growth across all regions: America’s (+18%), APAC (+76%), and EMEA (+43%) • Driven by improved sales funnel management and a renewed operat
Slide 8: Disciplined M&A Approach, Criteria
D i sci pl i ne d M &A A pp ro a c h, Cr i te r i a Deep and active funnel of strategic M&A opportunities to fuel long-term growth Customer, Markets Technology, Solution Commercial Customer Profile Application Space Commercialization • Pharma/CRO • Proteomics, multi-omics • Clear unmet need • CRO, C
Slide 9: Third Quarter 2022 Financial Results
Third Quarter 2022 Financial Results Vikram Jog, CFO Standard BioTools
Slide 10: Q3 2022 Revenue
Q3 2022 Revenue • Core product and service revenue (excluding Y/Y Q/Q COVID-19, Other) lower 3% 2022 2021 2022 Growth Growth y/y and increased 30% q/q (in $ millions) Q3 Q3 Q2 Instruments 7.9 9.5 4.3 -17% 84% • Instruments decreased Consumables 11.1 10.1 8.9 9% 24% 18% y/y but increased Service reve
Slide 11: Q3 2022 Revenue by Geographic Area
Q3 2022 Revenue by Geographic Area Y/Y Q/Q % of Change Change Total (in $ millions) 2022 2021 2022 Geographic Area Q3 Q3 Q2 Americas* 11.1 13.0 9.4 –15% 18% 43% EMEA 8.1 10.1 5.7 –20% 43% 31% Asia-Pacific 6.5 5.4 3.7 20% 76% 25% Total revenue 25.6 28.5 18.8 –10% 37% 100% *Americas geographic area in
Slide 12: For Research Use Only. Not for use in diagnostic procedures.
™ For Research Use Only. Not for use in diagnostic procedures. Information in this publication is subject to change without notice. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing t
Slide 13: Unleashing tools to accelerate breakthroughs in human health
Unleashing tools to accelerate breakthroughs in human health™ Standard BioTools